Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor (Escitalopram [Lexapro(R)]), a Dopamine and Noradrenaline Reuptake Inhibitor and Psychostimulant (Methylphenidate [Ritalin(R)]), an Anti-glutamatergic Drug Candidate (mGluR5 Antagonist RO4917523), and Placebo in Healthy Subjects.

Trial Profile

Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor (Escitalopram [Lexapro(R)]), a Dopamine and Noradrenaline Reuptake Inhibitor and Psychostimulant (Methylphenidate [Ritalin(R)]), an Anti-glutamatergic Drug Candidate (mGluR5 Antagonist RO4917523), and Placebo in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Basimglurant (Primary) ; Escitalopram; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder; Generalised anxiety disorder; Major depressive disorder; Narcolepsy
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Roche
  • Most Recent Events

    • 23 Jul 2011 NCT reports trial status as completed and actual end date as Jun 2011.
    • 18 Jan 2011 Actual patient number changed from 15 ato 25 as reported by ClinicalTrials.gov
    • 15 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top